Search

Your search keyword '"Zujun Li"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Zujun Li" Remove constraint Author: "Zujun Li" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
19 results on '"Zujun Li"'

Search Results

1. Distribution and transfusion efficacy of unexpected antibody

2. Coexistence of Large In-Plane and Out-of-Plane Piezoelectric Response in Group III–VI XMAY2 (X = I; M = Ti, Zr; A = Al, Ga; Y = S, Se) Monolayers

3. Evaluation of Brewing Suitability Quality of Different Guizhou He Varieties Based on Principal Component Analysis and Cluster Analysis

4. Adoption of adjuvant chemotherapy in <scp>high‐risk</scp> salivary gland malignancies

5. A Preliminary Validation of an Optimal Cutpoint in Total Number of Patient-Reported Symptoms in Head and Neck Cancer for Effective Alignment of Clinical Resources With Patients' Symptom Burden.

7. Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

8. Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

9. Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

10. Supplementary Table 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

11. Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

12. Data from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

13. Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

14. Supplementary Table 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

15. Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

16. The Evaluation of Educational Literacy of Physics Students in Normal Universities Under China’s Professional Certification System

17. Construction of industry knowledge graph based on graph theory

18. Research on Temperature Control of Mass Concrete for Multi-Tower Cable-Stayed Bridge Cap during Construction

19. The direction choice of green technological progress and late-development advantage in Central and Western China

Catalog

Books, media, physical & digital resources